secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2025-01-23T23:59:59+00:00
Accession:  0001437749-25-001727
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences reports 92.4% PVI success at ~3 months in nsPFA catheter feasibility study
--------------------------------------------------------------------------------

- 77 patients treated; first 30 evaluated at ~3 months remap with 92.4% PVI success (109/118 veins).
- 100% acute lesion success with conduction block; total PVI ablation time 11.6±4.5 minutes.
- 1 primary SAE (cardiac perforation) and 2 AEs (vertigo, creatinine elevation) all resolved.
- Company on track to begin IDE study in 2025 for clinical validation.
- Data presented at AF Symposium 2025; live case with 3D mapping on Abbott Ensite X System.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000143774925001727/0001437749-25-001727-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000143774925001727/plse20250121_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-001727

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer